Orforglipron
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Eli Lilly · Phase 1 · Completed · Enrollment 533
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2) | Obesity or overweight | n/r | 22 | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3) | Obesity or overweight | n/r | 22 | n/r | n/r |